Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of its drug setrusumab in clinical studies [1][2]. Allegations - The lawsuit claims that Ultragenyx provided overly positive information about the expected results of its Phase III Orbit and Cosmic Studies for setrusumab, which was intended to treat Osteogenesis Imperfecta (OI) [2]. - Defendants allegedly concealed material adverse facts about setrusumab's potential and the risks associated with the study protocols, leading to inflated stock prices [3]. Study Results - On December 29, 2025, Ultragenyx announced that the Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonates [4]. - Following this announcement, Ultragenyx's stock price dropped from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in one day [4]. Shareholder Actions - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [5]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [5].

Philadelphia, Pennsylvania--(Newsfile Corp. - February 18, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023 through December 26, 2025 (the "Class Period").Investor Deadline: Investors who purchased Ultragenyx common stock during the Class Period may, no later than ...

Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 - RARE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ultragenyx investors wh ...

New York, New York--(Newsfile Corp. - February 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a continge ...

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab during clinical trials [1][3]. Company Overview - Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [2]. Allegations of the Lawsuit - The lawsuit claims that Ultragenyx misrepresented the reliability of information regarding the effects of setrusumab on Osteogenesis Imperfecta (OI) patients and downplayed the risks associated with the Phase III Orbit study [3]. - It is alleged that Ultragenyx's optimism regarding the Phase III Orbit study's results was unfounded, as the company did not adequately disclose the risks of relying on Phase II results that lacked a placebo control [3]. Impact of Study Results - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [4]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ultragenyx common stock during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's management provided misleading information regarding the expected results of their Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that while setrusumab increased bone density, it did not correlate with a decrease in fracture rates, contrary to the positive statements made by the defendants [6]. - The misleading statements allegedly led to investors purchasing shares at inflated prices, resulting in damages when the true information became public [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of its drug, setrusumab, during the specified class period [2][3][5]. Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [2][5]. - The case is titled Bailey v. Ultragenyx Pharmaceutical Inc., et al, and is being heard in the United States District Court for the Northern District of California [2]. - Investors have until April 6, 2026, to file for lead plaintiff status [2][5]. Group 2: Allegations - The complaint alleges that Ultragenyx made false and misleading statements about the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients [3]. - It is claimed that Ultragenyx downplayed the risks associated with the Phase III Orbit study, which may not have achieved a statistically significant reduction in annualized fracture rate [3]. - The lawsuit asserts that the company's positive statements about its business and prospects were materially misleading and lacked a reasonable basis [3]. Group 3: Investor Actions - Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost [5][6]. - Investors can file to be lead plaintiff by the April 6, 2026 deadline or choose to remain absent from the class [6]. - The law firm offers a free case evaluation for investors who experienced losses related to Ultragenyx [6][7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about the efficacy of its drug setrusumab for Osteogenesis Imperfecta [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Ultragenyx to contact them directly to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Ultragenyx [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives made false and misleading statements regarding the effects of setrusumab, creating a false impression of reliable information while downplaying risks associated with the Phase III Orbit study [4]. - Ultragenyx's optimism regarding the Phase III Orbit study's results was deemed misplaced, as the company failed to adequately disclose risks related to the study's Phase II results, which lacked a placebo control group [4]. Group 3: Stock Performance Impact - On July 9, 2025, Ultragenyx announced that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [5]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [6][7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about clinical trial results [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $100,000 in Ultragenyx between August 3, 2023, and December 26, 2025, to contact them for legal options [1]. - A federal securities class action has been filed against Ultragenyx, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [4]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives misled investors by creating a false impression of reliable information regarding the effects of setrusumab on patients with Osteogenesis Imperfecta, while downplaying the risks of clinical trial failures [6]. - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [7]. - On December 29, 2025, Ultragenyx announced that both the Phase III Orbit and Cosmic Studies failed to meet primary endpoints, resulting in a further stock price decline of more than 42% [8][9].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. for the period between August 3, 2023, and December 26, 2025, due to alleged misleading statements regarding the company's drug setrusumab [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx provided investors with overly positive information about the expected results of its Phase III Orbit and Cosmic Studies for setrusumab, which is intended for treating Osteogenesis Imperfecta (OI) [5]. - Defendants allegedly made materially false and misleading statements about setrusumab's potential, claiming it would decrease the annualized fracture rate in OI patients, while concealing the true risks and limitations of the study protocols [6]. - The lawsuit asserts that these misleading statements led to Ultragenyx securities being purchased at artificially inflated prices, resulting in investor damages when the true information became public [6]. Group 2: Participation in the Class Action - Investors who purchased Ultragenyx common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. - A lead plaintiff must be appointed by April 6, 2026, to represent the interests of other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].